This strategic session will help practices move from understanding the CMA changes to deciding which medicines strategy is right for them, exploring the options, trade-offs, financial implications and evidence needed to make an informed decision. Using practical decision tools and a safe-space case discussion, we’ll help you develop a clear strategy, decide when to deploy it, and identify the triggers that might mean you need to change course.
Learning outcomes
By the end of the webinar, delegates will be able to:
- Evaluate the strategic options for medicines and understand the financial and client implications of each approach.
- Use practical frameworks and SPVS decision tools to identify the approach that best fits their practice.
- Develop a clear medicines strategy and implementation plan, including when to act, what evidence to monitor and what might trigger a change in direction
The SPVS CMA Working Group
The SPVS CMA Working Group – Pete Orpin, Kate Higgins and Vicki Farbon – has been closely involved in the CMA’s veterinary market investigation from its earliest stages through to the publication of the final remedies.
The group has provided the CMA with detailed evidence and practical insight into the realities of running veterinary practices. This has included contributing to discussions and formal hearings on transparency, pricing, prescription medicines, client choice, practice finances, regulation and the potential impact of proposed remedies on independent and start-up practices. The group has also undertaken detailed financial modelling and member research to understand the potential impact of changes to medicine supply and pricing, and maintained an ongoing dialogue with the CMA about the need for proportionate implementation, adequate transition periods and solutions that improve transparency and client choice without creating unintended consequences.
You can read Pete Orpin’s full bio here
You can read Vicki Farbon’s full bio here
Speakers:
Vicki Farbon & Pete Orpin
